JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oda, Y.
Right arrow Articles by Kharasch, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oda, Y.
Right arrow Articles by Kharasch, E. D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*METHADONE

Vol. 298, Issue 3, 1021-1032, September 2001

Metabolism of Methadone and levo-alpha -Acetylmethadol (LAAM) by Human Intestinal Cytochrome P450 3A4 (CYP3A4): Potential Contribution of Intestinal Metabolism to Presystemic Clearance and Bioactivation

Yutaka Oda and Evan D. Kharasch

Departments of Anesthesiology and Medicinal Chemistry, University of Washington, and the Puget Sound Veterans Affairs Medical Center, Seattle, Washington (E.D.K.); and Department of Anesthesiology, Osaka City University Medical School, Osaka, Japan (Y.O.)

Methadone and levo-alpha -acetylmethadol (LAAM) are opioid agonists used for analgesia and preventing opiate withdrawal. Methadone is sequentially N-demethylated to the inactive metabolites 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3-diphenylpyraline (EMDP). LAAM is essentially a prodrug that undergoes bioactivation via sequential N-demethylation to levo-alpha -acetyl-N-normethadol (nor-LAAM) and levo-alpha -acetyl-N,N-dinormethadol (dinor-LAAM). Methadone and LAAM are metabolized by CYP3A4 in human liver. Since they are administered orally, and CYP3A4 is expressed in human intestine, we tested the hypotheses that human intestine can metabolize methadone and LAAM, and evaluated the participation of CYP3A4. Intestinal microsomal methadone N-demethylation exhibited hyperbolic noncooperative kinetics and biphasic Eadie-Hofstee plots. Using a dual-enzyme Michaelis-Menten model, Km values were 11 and 1200 µM for EDDP and 23 and 930 µM for EMDP formation, respectively. CYP3A4 inhibitors (troleandomycin and ketoconazole) inhibited EDDP and EMDP formation by >70%. Methadone N-demethylation by CYP3A4 showed biphasic Eadie-Hofstee plots without evidence of positive cooperativity; Km values were 10 and 1100 µM for EDDP and 20 and 1000 µM for EMDP formation. Intestinal microsomal LAAM and nor-LAAM N-demethylation also exhibited hyperbolic kinetics and biphasic Eadie-Hofstee plots. Km values were 21 and 980 µM for nor-LAAM from LAAM and 18 and 1200 µM for dinor-LAAM from nor-LAAM. Troleandomycin and ketoconazole inhibited N-demethylation by >70%. LAAM and nor-LAAM metabolism by CYP3A4 showed biphasic Eadie-Hofstee plots without evidence of positive cooperativity; Km values were 8 and 1300 µM, 6 and 950 µM, respectively. Predicted in vivo intestinal extraction of methadone and LAAM is 21 and 33%, respectively. We conclude that methadone, LAAM, and nor-LAAM are metabolized by human intestinal microsomes; CYP3A4 is the predominant cytochrome P450 isoform; CYP3A4-catalyzed methadone, LAAM, and nor-LAAM metabolism is characterized by noncooperative, multisite kinetics; and intestinal metabolism may contribute to presystemic methadone inactivation and LAAM bioactivation.


0022-3565/01/2983-1021$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Mayo Clin Proc.Home page
H. S. Smith
Opioid Metabolism
Mayo Clin. Proc., July 1, 2009; 84(7): 613 - 624.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
S. De Fazio, L. Gallelli, A. De Siena, G. De Sarro, and M. G. Scordo
Role of CYP3A5 in Abnormal Clearance of Methadone
Ann. Pharmacother., June 1, 2008; 42(6): 893 - 897.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. A. Totah, K. E. Allen, P. Sheffels, D. Whittington, and E. D. Kharasch
Enantiomeric Metabolic Interactions and Stereoselective Human Methadone Metabolism
J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 389 - 399.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A.-M. Yu and R. L. Haining
EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF MOUSE CYP2D22
Drug Metab. Dispos., July 1, 2006; 34(7): 1167 - 1174.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
T. M. Klees, P. Sheffels, O. Dale, and E. D. Kharasch
METABOLISM OF ALFENTANIL BY CYTOCHROME P4503A (CYP3A) ENZYMES
Drug Metab. Dispos., March 1, 2005; 33(3): 303 - 311.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. N. Nanovskaya, S. V. Deshmukh, R. Miles, S. Burmaster, and M. S. Ahmed
Transfer of L-{alpha}-Acetylmethadol (LAAM) and L-{alpha}-Acetyl-N-normethadol (norLAAM) by the Perfused Human Placental Lobule
J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 205 - 212.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J.-S. Wang and C. L. DeVane
INVOLVEMENT OF CYP3A4, CYP2C8, AND CYP2D6 IN THE METABOLISM OF (R)- AND (S)-METHADONE IN VITRO
Drug Metab. Dispos., June 1, 2003; 31(6): 742 - 747.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.